• pharma
  • pharmapharma

Upcoming CONFERENCES

rss_Pharma.jpg
  1. Biobanking 2012

    Biobanking 2012

    9th - 10th February 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
    As researchers strive to develop more personalised medicines, the acquisition of high quality biospecimens is vital. This is reflected in the estimation that the biobanking market will be worth $19.13 bn by 2015. Harmonising biobank operations with better communication networks and global standardisation is imperative. The biobanking and biomolecular resources research infrastructure's new model for research estimates they will have approximately 200 biobanks operating across Europe by early 2012, complying with clearly defined responsibilities, quality standards and common procedures.

    ...more details
  2. 2nd Lyophilization Americas

    2nd Lyophilization Americas

    6th - 8th March 2012, The Seaport Hotel, Boston, USA
    With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend the market for lyophilizing compounds such as biologicals and biopharmaceuticals is currently approaching 200 million units and it is set to continue its year-on-year double digit growth. The lyophilisation market is expected to achieve significant growth from 2011 to 2021, owing primarily to greater demand for injectable biotech drugs and vaccine market expansion caused by the entry of new products and technologies.

    ...more details
  3. 10th Biosimilars Americas

    10th Biosimilars Americas

    13th - 15th March 2012, The Seaport Hotel, Boston, USA
    Biologics constitutes a major share of expenditure in the USA and globally. It is one of the fastest growing sectors of the pharmaceutical industry which corresponds to over 15% of the total pharmaceutical market. There is a large and potentially lucrative demand for lower cost biological drugs worldwide. With favourable regulatory developments, the biosimilar sector should pick up significantly, however, forming an important developing pharma market.

    ...more details
  4. 9th Annual Pain Management Conference

    9th Annual Pain Management Conference

    18th - 19th April 2012, Visiongain Conference Centre, London EC1, UK
    Pain is a global phenomenon which affects the quality of life that many people experience. It is not specific to any group, yet causes major disruptions in the workforce leading to economic and productivity losses. Pain management involves complex treatment sometimes with several medications and the input of a multidisciplinary team of health professionals. It also provides an ever expanding market for big pharma companies to provide new and more effective treatments.

    ...more details
  5. 6th Annual Diabetes Conference

    6th Annual Diabetes Conference

    25th - 26th April 2012, Thistle City Barbican, London, UK
    Diabetes still remains an incurable disease which is affecting an increasing number of people in the world. This provides an expanding and resilient market for pharmaceutical management of the disease. The US market alone is expected to grow from $56.7Bn to $73.6Bn from 2015 to 2021. Diabetes is now a global disease due to an increasingly aging and sedentary population, with strong growth expected in emerging markets that will drive near term growth in diagnostics and uptake of pharmaceuticals.

    ...more details
  6. 3rd Annual Pre-Filled Syringes Americas

    3rd Annual Pre-Filled Syringes Americas

    14th - 16th May 2012, Boston, USA
    The intravenous route of administration is the most effective route to administer medication fast and directly into the blood stream to facilitate the absorption and immediate onset of action, it also avoids 1st pass metabolism to increase the amount of active drug present. Other methods of administration may provide more comfort to the patient but have yet to be able reproduce the same rapid onset of action. Therefore parenteral administration is unlikely to be replaced in the near future.

    ...more details
  7. Cell Based Assays Americas

    Cell Based Assays Americas

    17th - 18th May 2012, Boston, USA
    Drugs recalls due to toxicity not only have a huge effect on the cost of developing new therapeutics but it also leads to many years of wasted research. That is why it is vital to get things right from the outset with more precise testing of new leads using more accurate in-vitro models. High Throughput Screening using biochemical assays has been a mainstay of the pharmaceutical industry in the past, but with the cost of developing a single lead reaching exorbitant amounts, it is now necessary to look at more cost-efficient methods that more accurately represent the in-vivo environment.

    ...more details
  8. 8th Monoclonal Antibodies

    8th Monoclonal Antibodies

    22nd - 24th May 2012, Thistle City Barbican, London, UK
    Generating annual sales of almost $50bn per year monoclonal antibodies continue to play a vital role in the biopharmaceutical development and represent 42% of the total market. Anticipated steady growth at an annual rate of 6.9% suggests the revenues will reach over $63bn/year by 2015. Primarily driven by the oncology and autoimmune disease treatments, the industry’s window will be significantly widened by the introduction of mAbs with novel indications and increasing penetration of the emerging economies.

    ...more details
  9. 2nd Annual Biobanking Americas 2012

    2nd Annual Biobanking Americas 2012

    12th - 14th June 2012, Boston, USA
    Biobanking offers immense opportunities for the entire pharmaceutical market, potentially opening ways to new drug discovery, and personalized medicine. It is not surprising the sector is expanding at such a rate that its total sales are predicted to triple in the next decade and reach $37.62bn by 2022, growing at CAGR of 15.7%. Visiongain's Biobanking Americas 2012 Conference will highlight the latest technological advances in the biobanking sector, most recent progress in the implementation of standard operating procedures, and current social perspective on the biobanking industry.

    ...more details
  10. Single-Use Bioreactors

    Single-Use Bioreactors

    19th - 20th June 2012, London, UK
    In the bioreactors market, disposables are one of the fastest growing sectors with the potential for many new breakthroughs and applications in the coming years. They are an attractive alternative to the traditional large inflexible stainless steel bioreactors which require substantial capital expenditure. The industry as a whole is experiencing an increased demand for biologics which requires the use of bioreactors to cultivate specific cell lines. The number of clinical monoclonal antibodies (mAbs) in development is increasing and pharmaceutical companies are looking at developing a diverse pipeline of mAbs to fill several smaller niches and meet the demand for personalised medicine rather than large scale production of blockbusters. This has resulted in the industry demanding smaller batch sizes, quicker turnover rates and cheaper production costs as budgets are restrained.

    ...more details

Past CONFERENCES

12
7th Annual Pharmacovigilance Conference

7th Annual Pharmacovigilance Conference

30th - 31st January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance of Pharmacovigilance has been apparent since the problems with thalidomide emerged in the 1960s. Since then, various high profile drug recalls, and estimations that more than 750,000 injuries and deaths each year in the US are caused by adverse drug reactions, have meant tightened regulatory controls.

...more details
5th Pharmaceutical Product Lifecycle Management

5th Pharmaceutical Product Lifecycle Management

24th - 25th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Research shows that pharmaceutical companies spend approximately 19% of their total revenue on activities that fall under the heading of pharmaceutical lifecycle management (PLM). With many blockbuster drugs drawing closer to the end of their patents, R&D new chemical entity output declining and the current economic climate; the utilisation of product lifecycle management is set to increase as pharmaceutical companies look for ways to optimise revenue.

...more details
5th Annual Recombinant Antibodies

5th Annual Recombinant Antibodies

17th - 19th January 2012, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
From Kohler and Millstein's pioneering efforts to today's multifactorial approach, monoclonal antibodies have consistently improved the clinical outcome of disease progression. As shown by Avastin and Lucentis, antibodies have blockbuster potential, now number eight of today's 20 top-selling biotech drugs. With ongoing growth rates nearing 15%, the global market will reach $74.7 by 2024 as new approvals and a growing world population drive patient demand.

...more details
5th Annual Contract Manufacturing

5th Annual Contract Manufacturing

7th - 8th December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
The importance and role of contract manufacturing has changed over the years from solely providing efficiencies in cost, capacity and time-to-market, or a specific expertise not available in-house to unique, innovative, and state-of-the-art processes and production technology to the pharmaceutical industry.

...more details
4th Annual Biomarkers

4th Annual Biomarkers

1st - 2nd December 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Forecasters predict significant growth in the global market of biomarkers with estimates of $26.5 billion by the year 2015. This growth will be driven by the current demand for biomarkers in drug discovery and other areas of R&D. The use of biomarkers during early stages of a product development is already saving costs and time in the industry by indicating the possibility of failure at an earlier stage in the research process. CROs have now recognised the commercial opportunities of biomarkers and are forming partnerships with providers and building in-house capabilities.

...more details
5th Annual Stability Testing

5th Annual Stability Testing

3rd - 4th November 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, UK
Pharmaceutical companies are under intense pressure to provide safe, effective medicines for patient consumption while also maintaining adherence to stringent regulatory and quality requirements. Stability testing is a highly integral part of pharmaceutical product development which constitutes one of the fastest growing markets in the pharmaceutical and biotechnology sectors.

...more details
3rd Annual Vaccine Manufacturing

3rd Annual Vaccine Manufacturing

27th - 28th October 2011, Thistle City Barbican, London, UK
The global vaccine market will achieve sustained growth over the next 15 years, and this trend is likely to continue as governments recognise the importance of mass vaccination. Visiongain's 3rd Annual Vaccine Manufacturing conference will feature key industry experts, who will assess the current landscape of vaccine development and address challenges faced by manufacturers.

...more details
4th Pre-Filled Syringes

4th Pre-Filled Syringes

17th - 19th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
Join us at Visiongain's 4th Pre-filled syringes conference and gain insight into a spectrum of topical issues ranging from manufacture, formulation and drug identity to quality, safety and novel pre-filled syringe technologies.

...more details
2nd Annual Cell-Based Assays 2011

2nd Annual Cell-Based Assays 2011

11th - 13th October 2011, Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS
It takes well over £500 million and between 10 and 12 years to develop a new drug. For every million compounds screened, approximately 250 make it to pre-clinical testing, 10 advance to clinical trials and just one is approved for patient use. Industry can ill-afford to continue such a wasteful process.

...more details
9th Biosimilars

9th Biosimilars

5th - 7th October 2011, Thistle City Barbican, London, UK
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars.

...more details
12